Germline humanization of a murine Aβ antibody and crystal structure of the humanized recombinant Fab fragment

@article{Robert2010GermlineHO,
  title={Germline humanization of a murine A$\beta$ antibody and crystal structure of the humanized recombinant Fab fragment},
  author={R. Robert and V. Streltsov and J. Newman and L. Pearce and K. Wark and O. Dolezal},
  journal={Protein Science},
  year={2010},
  volume={19}
}
Alzheimer's disease is the most common form of dementia, affecting 26 million people worldwide. The Aβ peptide (39–43 amino acids) derived from the proteolytic cleavage of the amyloid precursor protein is one of the main constituents of amyloid plaques associated with disease pathogenesis and therefore a validated target for therapy. Recently, we characterized antibody fragments (Fab and scFvs) derived from the murine monoclonal antibody WO‐2, which bind the immunodominant epitope (3EFRH6) in… Expand
His‐tag binding by antibody C706 mimics β‐amyloid recognition
TLDR
A monoclonal antibody C706 is developed, which recognizes the human Aβ peptide, and the mode of his‐tag binding by C706 resembles the Aβ recognition by antibodies PFA1 and WO2. Expand
Structural studies of the tethered N‐terminus of the Alzheimer's disease amyloid‐β peptide
TLDR
This novel structure has the potential to provide a foundation for investigating the effect of metal ion binding to Aβ and illustrates a potential target for the development of future Alzheimer's disease therapeutics aimed at stabilizing the N‐terminal monomer structure, in particular residues His13 and His14. Expand
humMR1, a highly specific humanized single chain antibody for targeting EGFRvIII.
Production of an efficient humanized single chain antibody is reported here to specifically target EGFRvIII, a truncated receptor expressed in a wide variety of human cancers. CDR loops of MR1, aExpand
Engineered antibody approaches for Alzheimer's disease immunotherapy.
TLDR
This review will address recent progress using recombinant antibodies against Aβ, highlighting their advantages over conventional monoclonal antibodies and delivery methods. Expand
Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid β peptide.
TLDR
It is demonstrated that an aromatic residue at position H58 in the antibody is essential in the recognition of Aβ and Fabs based on germline V-genes bind to Aβ monomers with a low affinity. Expand
Application of Antibody Fragments Against Aβ With Emphasis on Combined Application With Nanoparticles in Alzheimer’s Disease
TLDR
The combination of nanoparticles and antibody fragments against amyloid-β can be used in the diagnosis and treatment of Alzheimer’s disease, focusing on the combined application with nanoparticles. Expand
Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1
TLDR
The generation of Fpro0165, a human anti-formyl peptide receptor 1 (FPR1) antibody generated by variable domain engineering of an antibody derived by immunization of transgenic mice expressing human variable region genes is described. Expand
In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development
TLDR
The BA11 domain, BA11, exhibited negligible antigenicity, high stability and high affinity for mouse, rat, and HSA, and was established as a clinical candidate. Expand
Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design.
TLDR
The hG7-BM3-VcMMAE conjugate, which was shown to induce tumor cell apoptosis and effectively suppress nude mice bearing HCC xenografts, is generated, providing new inspiration for antibody humanization and an ADC candidate for laboratory study and clinical applications. Expand
Design, expression and characterization of a single chain anti-CD20 antibody; a germline humanized antibody derived from Rituximab.
TLDR
The production and characterization of a humanized single chain version of Rituximab with the ability to inhibit growth of CD20-expressing cancer cell may provide a promising alternative strategy for CD20 targeted therapy. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 44 REFERENCES
Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.
TLDR
E engineered antibody fragments derived from the monoclonal antibody, WO-2 which recognises an epitope in the N-terminal region of Abeta have immunotherapeutic potential and are able to prevent amyloid fibrillisation and inhibit Abeta oligomer-mediated neurotoxicity in vitro as efficiently as the whole IgG molecule. Expand
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
TLDR
Results indicate that antibodies can cross the blood–brain barrier to act directly in the central nervous system and should be considered as a therapeutic approach for the treatment of Alzheimer disease and other neurological disorders. Expand
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
TLDR
An apparently full-length complementary DNA clone coding for the A4 polypeptide is isolated and sequenced and suggests that the cerebral amyloid deposited in Alzheimer's disease and aged Down's syndrome is caused by aberrant catabolism of a cell-surface receptor. Expand
Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope.
TLDR
The three-dimensional structure, to near atomic resolution, of both the antibody and the complex with its antigen, the A beta peptide is determined, which reveals the molecular basis for WO2 recognition and binding of A beta. Expand
The F(ab′)2 fragment of an Aβ-specific monoclonal antibody reduces Aβ deposits in the brain
TLDR
It is suggested that effective in vivo clearance of amyloid deposits can be achieved without stimulation of FcR-reactive phagocytes or activation of the complement cascade. Expand
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
TLDR
It is reported that immunization of the young animals essentially prevented the development of β-amyloid-plaque formation, neuritic dystrophy and astrogliosis, and treatment of the older animals markedly reduced the extent and progression of these AD-like neuropathologies. Expand
Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering.
TLDR
The final 35PA83 derivative had a GI higher than that of a fully human Fab, which had neutralization properties similar to35PA83 and which was used as a benchmark in this study. Expand
Thermodynamic Consequences of Mutations in Vernier Zone Residues of a Humanized Anti-human Epidermal Growth Factor Receptor Murine Antibody, 528*
TLDR
The results suggest that Vernier zone residues make enthalpic contributions to antigen binding and that the regulation of conformational entropy changes upon humanization of murine antibodies must be carefully considered and optimized. Expand
Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay*
TLDR
It is found that CSF βA4 1-42 level is lower in AD patients compared with non-demented controls, although there was a significant overlap between the groups. Expand
Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.
TLDR
Reports from the active immunization clinical trial indicated that, similarly to effects observed in mouse studies, amyloid levels in brain were reduced. Expand
...
1
2
3
4
5
...